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Abstract
Background: To report the clinical outcome of high dose rate brachytherapy as sole treatment for clinically
localised prostate cancer.
Methods: Between March 2004 and January 2008, a total of 351 consecutive patients with clinically localised
prostate cancer were treated with transrectal ultrasound guided high dose rate brachytherapy. The prescribed dose
was 38.0 Gy in four fractions (two implants of two fractions each of 9.5 Gy with an interval of 14 days between the
implants) delivered to an intraoperative transrectal ultrasound real-time defined planning treatment volume.
Biochemical failure was defined according to the Phoenix Consensus and toxicity evaluated using the Common
Toxicity Criteria for Adverse Events version 3.
Results: The median follow-up time was 59.3 months. The 36 and 60 month biochemical control and metastasis-
free survival rates were respectively 98%, 94% and 99%, 98%. Toxicity was scored per event with 4.8% acute Grade 3
genitourinary and no acute Grade 3 gastrointestinal toxicity. Late Grade 3 genitourinary and gastrointestinal toxicity
were respectively 3.4% and 1.4%. No instances of Grade 4 or greater acute or late adverse events were reported.
Conclusions: Our results confirm high dose rate brachytherapy as safe and effective monotherapy for clinically
organ-confined prostate cancer.
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Background
In patients with clinically localised prostate cancer, high
dose rate (HDR) brachytherapy (BRT) has emerged as a
safe and effective monotherapeutic modality [1-8]. It has
shown PSA relapse-free survival rates which are compar-
able to those of patients treated with permanent low
dose rate (LDR) BRT [9-11], external beam radiotherapy
(EBRT) [12-14] or radical prostatectomy [15]. In the
absence of randomised clinical trials of sufficient size,
however, the optimal therapeutic strategy for organ-
confined disease remains controversial and treatment
assignment appears influenced by physician bias and pa-
tient preference. In addition, despite publications of mature
results revealing superior outcomes for HDR monotherapy
over a range of risk groups [1-3,8,16], a variety of dose
schedules and of risk definitions make uniform recommen-
dations concerning the optimal dose regime difficult.
Therefore, the objective of the present study was to con-
tribute to available experience by reporting our mature re-
sults of HDR BRT in 351 consecutive patients treated with
a hypofractionated two-implant treatment regime.
Methods
Patient selection and characteristics
Since 2002, we have treated more than 900 patients with
HDR monotherapy for clinically localised prostate cancer.
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implemented reflecting an evolution aiming to im-
prove clinical workflow and patient comfort. From January
2002 to February 2004, 141 patients were treated with one
implant of four fractions of 9.5 Gy. From March 2004 to
January 2008, 351 patients received two implants, separated
by two weeks, each of two fractions of 9.5 Gy. From
February 2008 to the present, our HDR monotherapy re-
gime consists of three implants, spaced by three weeks,
each of a single fraction of 11.5 Gy. This paper analyses in
detail the clinical outcome of our two-implant approach
during the four-year time frame of 2004–2008 when
we treated consecutively a cohort of 351 patients. The
description of the other two protocols with limited com-
parative analysis of the outcomes of all three protocols is
the subject of a different study [17].
All 351 patients had histologically proven disease and
were staged according to the American Joint Committee
on Cancer, 6
th edition, staging guidelines. Pre-treatment
staging included digital rectal examination, transrectal
ultrasound (TRUS) and, if clinically indicated, computed
tomography (CT)/magnetic resonance imaging (MRI)
and bone scintigraphy. The Memorial Sloan Kettering
group definition was used to classify patients into risk
groups [18].
Eligibility criteria were clinically and radiographically
organ-confined disease with freedom from lower urinary
tract symptoms requiring treatment. In the case of high-
risk patients, treatment was performed in men who
rejected prostatectomy or EBRT, or who were not con-
sidered suitable for prostatectomy or definitive dose-
escalated EBRT. However, treatment assignment was in
all cases at the discretion of the treating physician.
Patients were considered ineligible for monotherapy in
cases of nodal or other distant metastases, previous
pelvic EBRT for another malignant diagnosis or previous
open surgery of the prostate.
A total of 70 patients (19.9%) received androgen
deprivation therapy (ADT), 44 (62.8%) of whom were
high-risk, 19 (27.1%) intermediate-risk, and seven (10%)
low-risk. Hormonal therapy was prescribed neoadjuvantly
and continued concurrently with radiation and adjuvantly
for an overall duration of median nine months (range,
3–14 months). The duration of ADT for the subgroups of
low-risk, intermediate-risk, and high-risk patients was 4
months (range, 3–6 months), 6 months (range, 6–10
months) and 9 months (range, 9–14 months), respectively.
Final decisions concerning hormonal treatment were
made by the referring urologists. Patient and tumour
characteristics are shown in Table 1.
Brachytherapy protocol
Transperineal implantation was performed under TRUS
guidance using a continuous probe movement technique
[19]. For preplanning, transversal ultrasound images of
the prostate, urethra and anterior rectal wall were ac-
quired in real-time and three-dimensional (3D) volumes
reconstructed based on 1.0 mm image distance. The
planning target volume (PTV) was defined as the entire
prostate gland without margins. Based on the acquired
3D anatomy, the appropriate virtual needle positions
were generated using the intraoperative treatment plan-
ning system SWIFT (Nucletron B.V., Veenendaal, The
Netherlands). Afterwards the needle source dwell posi-
tions located within the prostate gland were activated
Table 1 Patient and tumour characteristics (n=351)
Characteristics
Median follow-up (months) 59.3 (16.5-82.6)
Gland volume at implant (cc)
mean 41
median 39 (16–107)
Age at treatment (years)
mean 67.7
median 68.4 (44.1-82.2)
Pre-treatment PSA (ng/ml)
mean 7.1
median 6.4 (2.0-34.1)
n (%)
Stage
T1b-c 129 (36.7%)
T2a 113 (32.1%)
T2b 55 (15.6%)
T2c 53 (15.0%)
T3a 1 (0.2%)
Gleason score
≤ 6 281 (80.0%)
7 62 (17.6%)
> 7 8 (2.2%)
Pre-treatment PSA (ng/ml)
≤ 10 324 (92.3%)
11-20 23 (6.5%)
> 20 4 (1.1%)
Age at treatment (years)
< 60 51 (14.5%)
60-69 169 (48.1%)
≥ 70 131 (37.3%)
Androgen deprivation therapy 70 (19.9%)
Risk group
Low 196 (55.8%)
Intermediate 81 (23.0%)
High 74 (21.0%)
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an anatomy-based optimisation algorithm. Dose volume
histograms (DVHs) for prostate, urethra, and rectum were
calculated for evaluation of the anatomy-based dose opti-
misation. As the preplanning dosimetry parameters ful-
filled our dosimetric protocol (Table 2), TRUS guided
implantation of steel needles (200 mm length, 1.9 mm
diameter) was performed at the previously determined po-
sitions. After completion of implantation, a final 3D ultra-
sound data set was acquired (1.0 mm image acquisition)
for intraoperative TRUS based real-time treatment plan-
ning. Prostate and organs at risk (OAR, i.e., rectum, ur-
ethra, bladder) contouring was checked and updated
according to the new acquired image set. Real needle posi-
tions were reconstructed and dwell positions located
within the prostate gland activated (Figure 1a). Using the
anatomy-based optimisation tool of SWIFT the dwell
times were automatically adjusted ensuring the resulted 3D
dose distribution fulfilled our PTV coverage requirements
in compliance with OAR dose constraints (Figure 1b).
Evaluation of implant conformity was based on dose-
volume parameters for the PTV and OARs. Dose specifi-
cation was given as the mean dose on the PTV surface.
The prescribed reference dose was 9.5 Gy delivered four
times to a total dose of 38.0 Gy using two implants. The
implants were spaced by two weeks, each delivering two
treatment fractions with an interfraction interval of 6
hours. Dosimetry assessment parameters and OAR con-
straints are shown in Table 2.
All implants were performed under spinal, or if indi-
cated, general anaesthesia with the patient in the high lith-
otomy position using a perineal template. All treatments
were performed using an
192Iridium HDR afterloading sys-
tem (microSelectron-HDR, Nucletron). Written informed
consent was obtained from all patients. In our series we
had one patient with T3 disease, who was staged T3a. The
PTV in this case was defined by the prostate capsule plus
5.0 mm in all directions (except for the posterior rectal
margin). This was to cover extracapsular invasion as con-
firmed on pre-treatment pelvic MRI.
Follow-up and statistical analysis
Initial follow-up was performed at six weeks after the
last BRT fraction and then every three months for the
first year, every six months for the second year and
annually thereafter. Patient data was collected from a
prospectively maintained database and by retrospective
clinical chart review with data collection allowing
also information acquisition from referring urologists.
Toxicity analysis for gastrointestinal and genitourinary
sites was performed using the National Cancer Institute
Common Toxicity Criteria for Adverse Events, version
3. Follow-up for this analysis was completed during
October 2010. During September and October 2010 all
patients also received either at follow-up visits or by
mail, a final questionnaire in order to assess the PSA sta-
tus and to assess whether the last documented adverse
events were persistent or not.
Acute toxicity was defined as symptoms that had com-
pletely resolved by six months after BRT. Adverse events
that persisted or appeared beyond six months were
considered late toxicity. Toxicity was scored per event
and the highest value noted during follow-up was
selected to calculate toxicity percentages. Biochemical
relapse was defined according to the Phoenix definition
(sustained post-treatment PSA value > nadir +2 ng/ml)
[20]. Potency was defined as the ability to achieve an
erection that was sufficient for intercourse. The esti-
mated likelihood of events was calculated using the
Kaplan-Meier method and comparisons made using the
log-rank test. A two-sided P value ≤ 0.05 was considered
statistically significant. For the multivariate analysis we
used the Cox proportional hazards model.
Results
Clinical outcome
Of the 351 patients, 21 (5.9%) developed biochemical re-
lapses with five (1.4%) developing distant metastatic dis-
ease. The estimated biochemical control (BC) was 98%
at 36 months and 94% at 60 months. The estimated
overall survival and metastasis-free survival were re-
spectively 98%, 98% and 99%, 98% at 36 and 60 months.
Survival and BC results are shown in Figure 2a.
The BC at 60 months according to risk group was
94%, 92%, and 92% for low-, intermediate- and high-risk
patients respectively which did not achieve statistical
significance, (P = 0.38, Figure 2b). The Kaplan-Meier es-
timates of BC at 60 months for the subgroup of high-
risk patients who received ADT was 94% and 89% for
patients without ADT, (P = 0.09). This was suggestive of
Table 2 Dosimetry parameters of the brachytherapy protocol with total physical prescription dose (Gy) and normal
tissue dose constraints (as percentages of the prescribed reference dose)
Treatment
scheme
PTV D10/D 0.1 cm
3 D10/D 0.1 cm
3 D10/D 0.1 cm
3 D90 V100 V150
Rectum Bladder Urethra
9.5 Gy x 4 38.0 Gy ≤ 75% / ≤ 80% ≤ 75% / ≤ 80% ≤ 115% / ≤ 120% ≥ 100% ≥ 90% ≤ 35%
PTV = planning target volume; D10-Rectum = dose delivered to 10% of the rectum; D10-Bladder = dose delivered to 10% of the bladder; D10-Urethra = dose
delivered to 10% of the urethra; D 0.1 cm
3 = minimum dose to the most exposed 0.1 cm
3 of the organ; D90 = dose delivered to 90% of the PTV ; V100,
V150 = percentage of PTV receiving 100% and 150% of the prescription dose.
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statistical significance. The Kaplan-Meier estimates of
BC at 60 months according to pre-treatment PSA were
93%, 100% and 100% for patients with an initial PSA
of ≤ 10, 11–20 and > 20 ng/ml, (P = 0.43). There was
hence no statistically significant difference. The BC
according to clinical stage was 94%, 92% and 92% for pa-
tients staged ≤ T2a, T2b and ≥ T2c, (P = 0.37). Again,
there was no statistically significant difference. The BC at
60 months according to Gleason score was 94%, 89% and
100% for patients with a Gleason score of ≤ 6, 7 and > 7,
(P = 0.27) and also did not achieve statistical significance.
Characteristics used for multiple regression analyses to
correlate with BC were clinical T stage (≤ T2a, T2b, ≥
T2c), Gleason Score (≤ 6, 7, > 7), pretreatment-PSA (≤
10, 11–20, > 20 ng/ml) and ADT. The multivariate Cox
regression analyses could not identify independent prog-
nostic factors for biochemical failure.
The median follow-up was 59.3 months with 350, 340,
252 and 166 patients reaching the 24, 36, 48 and 60
month survival time points. Final follow-up question-
naires were returned by 344 (98%) patients during
November and December 2010. Seven (2%) patients
were not alive at the time of reporting. Follow-up details
are given in Table 1.
Toxicity
Table 3 shows the distribution of acute toxicity for the
total group of 351 patients. Part of the data was
presented at the 2007 German Society of Radiation On-
cology meeting [21]. Table 4 shows the results for late
morbidity. Seven (1.9%) patients developed late Grade 3
Figure 2 Kaplan-Meier actuarial analysis of all 351 patients for:
(a) Biochemical control, overall survival and metastasis-free
survival and (b) Biochemical control by risk group. Figure 1 Intraoperative real-time treatment planning. (a) Three-
dimensional reconstruction of the prostate, organs at risk (i.e.,
rectum, urethra, bladder), in situ needles and the intraprostatic
source dwell positions as calculated using SWIFT for the final
treatment plan. Contour definition for rectum extended 10 mm
cranially from the prostatic base and 10 mm caudally from the
prostatic apex. Urethra contouring encountered the intraprostatic
urethra marked by the insertion of a three-way Foley catheter
and extended by 5 mm caudally to include the apical urethra
membrane. (b) Isodose distribution after anatomy-based dose
optimisation. The isodose colour code convention is: dark
red = 300% {isodose = 28.5 Gy}; orange = 200% {isodose =19.0 Gy};
yellow = 150% {isodose = 14.25 Gy}; turquoise = 100%
{isodose = 9.5 Gy}. The 100% isodose was set to encompass
the red delineated prostate capsule.
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strictures. Another four (1.1%) patients developed late
Grade 3 gastrointestinal toxicity, two of whom had
endoscopically verified Grade 3 rectal mucositis. Treat-
ment included endoscopic restoration of bowel continu-
ity in one patient and a laser coagulation procedure for
rectal bleeding in another patient. No Grade 4 or higher
acute or late toxicities occurred.
Erectile dysfunction Grade 3, defined as a medically
assisted erectile dysfunction inadequate for intercourse,
was reported by 19 (5.4%) patients prior to BRT. Of the
332 patients who reported Grade 0–2 erectile dysfunc-
tion prior to treatment, 39 (11.1%) confirmed a decline
to Grade 3 after BRT. In the final questionnaire 293
patients (83.4%) reported an erection adequate for
intercourse achieved with or without the use of erectile
aids.
Discussion
Emerging radiobiological data indicates that prostate
cancer has a low a/β-ratio of 1.2-3.0 Gy [22-24],
suggesting that biological dose escalation can be
achieved by hypofractionated treatment schemes.
In that context, HDR BRT optimally exploits the
radiobiological advantage of large fraction sizes while
ensuring superior dose conformality. It enables 3D
anatomy-based optimisation of the dose distribution
by accurately controlling the radiation source position-
ing and modulating source dwell times. This permits
excellent target coverage while at the same time
minimizing dose to critical structures which can occur
w i t hL D RB R Td u et os o u r c em i g r a t i o na n dt i s s u ed e f o r m -
ities [25].
The results from this study confirm HDR monotherapy
as an excellent option for the definitive treatment of local-
ised prostate cancer. The reported 94% BC at 60 months is
in accordance with mature HDR monotherapy data from
other institutions, suggesting high PSA relapse-free survival
rates for all risk groups. In fact, consistent and reproducible
five-year BC rates have been reported for patients with low-
risk (85-97%), intermediate-risk (93-97%), and high-risk
(79–88%) localised disease [1-8,16,26,27]. Even though dir-
ect comparisons are difficult, our results are consistent with
the experiences of other groups using a similar two-implant
approach. Mark et al. [1] reported an actuarial BC rate of
88% at eight years in 301 patients for all risk groups
utilising two implants at three fractions of 7.5 Gy. Rogers
et al. [8] reported a BC rate of 94% at five years in 284
intermediate-risk patients treated with two implants at
three fractions of 6.5 Gy. Both institutions included clinical
stages ≥ T2b with no exclusions for Gleason score or pre-
treatment PSA in the series by Mark et al. [1]. These re-
cently published data reflect that HDR monotherapy is ap-
plicable in intermediate as well as selected localised high-
risk cases.
In our cohort, Gleason score, pre-treatment PSA, and
clinical stage did not attain statistical significance using
Kaplan-Meier actuarial estimates of freedom from bio-
chemical failure. Rogers et al. [8], Hoskin et al. [3] and
Yoshioka et al. [2] likewise failed to verify Gleason score
and pre-treatment PSA or clinical stage as significant
predictors of risk of biochemical failure. Hoskin et al. [3]
reported on a group of 197 patients with a four-year BC
rate of 87% in 86 high risk-cases. Those included clinical
stages ≥ T3 in 21%, Gleason score ≥ 8 in 10%, and
PSA > 20 in 25% of cases with 92% of high-risk patients
receiving temporary ADT. In our study, the BC at 60
months for low-risk, intermediate-risk and high-risk pa-
tients was 94%, 92% and 92%, respectively. There was
no statistically significant difference between these risk
groups, indicating that all patients benefited equally.
However, 60% of the high-risk patients received tempor-
ary ADT including all patients with PSA ≥ 20 ng/ml,
93% of patients with Gleason score ≥ 7b (4+3), and 52%
of all cases staged > T2b. At this point, the potential ad-
vantage of short term androgen suppression for high-
Table 3 Acute toxicity results (n= 351)
Toxicity
Grade Gastrointestinal Genitourinary
Grade 5 0% 0%
Grade 4 0% 0%
Grade 3 0% 17 (4.8%)
Grade 2 6 (1.7%) 58 (16.5%)
Grade 1 55 (15.7%) 169 (48.1%)
Table 4 Late toxicity results (n = 351)
Grade
Toxicity 1 2 3 4
Genitourinary
Frequency/Urgency 105
(29.9%)
17
(4.8%)
2
(0.6%)
-
Dysuria 17
(4.8%)
4
(1.1%)
2
(0.6%)
0
Incontinence 30
(8.6%)
18
(5.1%)
1
(0.3%)
0
Retention 59
(16.8%)
19
(5.4%)
7
(2.0%)
0
Errectile Dysfunction 85
(24.2%)
55
(15.7%)
58
(16.5%)
-
Gastrointestinal (Rectum)
Pain 7
(2.0%)
1
(0.3%)
1
(0.3%)
0
Mucositis/Necrosis 0 3
(0.8%)
4
(1.2%)
0
Diarrhea 0 0 0 0
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no corroborative evidence exclusive to this modality
exists.
Gastrointestinal and genitourinary morbidity was low in
our series with toxicity incidences across all scales consist-
ent with those reported by other authors [1-3,5,8]. We en-
countered 3.4% late Grade 3 genitourinary toxicity with
seven patients developing strictures requiring urethrotomy.
Late Grade 3 rectal morbidity was 1.4% overall with one pa-
tient requiring endoscopic restoration of bowel continuity
after rectal biopsy associated ulcer development. Addition-
ally, in the final questionnaire 83.4% of patients reported
erectile function, with or without the use of medical aids,
suitable for intercourse. This ra t eo fe r e c t i l ep r e s e r v a t i o ni s
consistent with data reported in recent publications on
HDR monotherapy [8,26,27]. The consistently low level of
severe acute and late toxicities in HDR BRT likely reflects
the precision of 3D dosimetry, which can reduce uncertain-
ties in dose distribution and thereby allow for better sparing
of critical organs [28].
In accordance with the experience of other groups
[8,28-30], neither larger gland size nor previous trans-
urethral resection of the prostate (TURP) were absolute
contraindications for treatment. The transperineal ap-
proach in high dorsal lithotomy position enables ad-
equate implantation of volumes appreciably greater than
50 cc provided there is a sufficiently broad pelvic inlet
and low pre-treatment urinary symptom scores. In the
same way, implantation at six months after TURP was
safely feasible given a sufficient amount of residual gland
volume.
There are of course some limitations in our study. It
encompassed 351 patients who were not treated within
a multi-institutional framework but at a single tertiary-
care center. The data was generated from a prospectively
maintained database which was analysed by retrospect-
ive chart review. Our treatment modality has also limi-
tations. Intraprostatic calcifications may impair TRUS
imaging quality thereby limiting real-time US-based treat-
ment planning and dose conformality. Therefore, the
“technical eligibility” of each patient should be evalu-
ated through a TRUS examination prior to treatment.
Finally, the presence of seminal vesicle invasion or large
prostate gland volumes extending beyond the bony pel-
vic inlet, also disqualify patients for monotherapy [28].
Conclusions
The findings of the present analysis confirm mono-
therapeutic HDR BRT to be a safe and effective modality
for clinically localised prostate cancer. Three-dimensional
TRUS-based intraoperative real-time treatment planning
provided accurate dosimetry with precise radiation delivery
ensuring an acceptable side effect profile.
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